On-line bottom-up approaches have recently emerged as promising alternatives to standard off-line processes for characterizing post-translational modifications (PTMs) of therapeutic monoclonal antibodies (mAbs). The benefits of on-line processing include reductions in required sample amount and sample handling, as well as reducing the overall turnaround time. However, shortening digestion time for the on-line approach of an intact mAb can cause incomplete peptide cleavages, leading to low sequence coverage and poor repeatability of analyses. For the first time, we describe a novel, automated targeted bottom-up strategy consisting of reducing the complexity of intact mAb by digesting the product into small ∼25 kDa fragments, followed by an o...
The Consortium for Top-Down Proteomics (www.topdownproteomics.org) launched the present study to ass...
For therapeutic monoclonal antibodies (mAbs), detailed analysis of the structural integrity and hete...
Monoclonal antibodies (mAbs) represent one of the fastest growing areas of new drug development.Howe...
The identification and quantification of post-translational modifications (PTMs) is a crucial step r...
We describe quantitative characterization of a sample preparation platform for rapid and high-throug...
Characterization of post-translational modifications (PTMs) of therapeutic antibodies is commonly pe...
Fully automated analysis of multiple structural attributes of monoclonal antibodies (mAbs) using thr...
The development of biotherapeutic proteins requires the use of efficient analytical methods to suppo...
Glycosylation is a common post-translational modification of therapeutic monoclonal antibodies produ...
The Consortium for Top-Down Proteomics (www.topdownproteomics.org) launched the present study to ass...
The promising pipeline of therapeutic monoclonal antibodies (mAbs) demands robust bioanalytical meth...
The Consortium for Top-Down Proteomics (www.topdownproteomics.org) launched the present study to ass...
For therapeutic monoclonal antibodies (mAbs), detailed analysis of the structural integrity and hete...
Significant growth of biopharmaceuticals requires powerful analytical methods to better understand t...
The full analytical characterization of therapeutic monoclonal antibodies (mAbs) requires a large va...
The Consortium for Top-Down Proteomics (www.topdownproteomics.org) launched the present study to ass...
For therapeutic monoclonal antibodies (mAbs), detailed analysis of the structural integrity and hete...
Monoclonal antibodies (mAbs) represent one of the fastest growing areas of new drug development.Howe...
The identification and quantification of post-translational modifications (PTMs) is a crucial step r...
We describe quantitative characterization of a sample preparation platform for rapid and high-throug...
Characterization of post-translational modifications (PTMs) of therapeutic antibodies is commonly pe...
Fully automated analysis of multiple structural attributes of monoclonal antibodies (mAbs) using thr...
The development of biotherapeutic proteins requires the use of efficient analytical methods to suppo...
Glycosylation is a common post-translational modification of therapeutic monoclonal antibodies produ...
The Consortium for Top-Down Proteomics (www.topdownproteomics.org) launched the present study to ass...
The promising pipeline of therapeutic monoclonal antibodies (mAbs) demands robust bioanalytical meth...
The Consortium for Top-Down Proteomics (www.topdownproteomics.org) launched the present study to ass...
For therapeutic monoclonal antibodies (mAbs), detailed analysis of the structural integrity and hete...
Significant growth of biopharmaceuticals requires powerful analytical methods to better understand t...
The full analytical characterization of therapeutic monoclonal antibodies (mAbs) requires a large va...
The Consortium for Top-Down Proteomics (www.topdownproteomics.org) launched the present study to ass...
For therapeutic monoclonal antibodies (mAbs), detailed analysis of the structural integrity and hete...
Monoclonal antibodies (mAbs) represent one of the fastest growing areas of new drug development.Howe...